-
plants of the
genus Maytenus.
Derivatives of
maitansine are
known as
maytansinoids. Some are
being investigated as the
cytotoxic component of antibody-drug...
-
called DM1 (and in some of its
forms emtansine), is a thiol-containing
maytansinoid that for
therapeutic purposes is
attached to a
monoclonal antibody through...
- Blättler WA, et al. (January 1992). "Immunoconjugates
containing novel maytansinoids:
promising anticancer drugs".
Cancer Research. 52 (1): 127–31. PMID 1727373...
- conjugate. It is the anti-CD138
chimerized MAb (nBT062)
linked to the
maytansinoid DM4. It is
being investigated as part of a
treatment for
multiple myeloma...
-
single trastuzumab molecule with
several molecules of DM1, a
cytotoxic maytansinoid, attached. SMCC, or
succinimidyl trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate...
-
approved ADCs with
ImmunoGen technology employ one of the company's
maytansinoid cell-killing agents,
either DM1 or DM4, or one of the company's DNA-acting...
- It
comprises the CD56-binding antibody,
lorvotuzumab (huN901), with a
maytansinoid cell-killing agent, DM1,
attached using a
disulfide linker, SPP. (When...
- with
myotonic dystrophy in ways not yet well
understood Mertansine, a
maytansinoid cytotoxic agent used in
trastuzumab emtansine and
other antibody-drug...
- RV,
Lambert JM,
Rowinsky EK (January 2003). "Cantuzumab mertansine, a
maytansinoid immunoconjugate directed to the
CanAg antigen: a
phase I, pharmacokinetic...
- "Eradication of
large colon tumor xenografts by
targeted delivery of
maytansinoids".
Proceedings of the
National Academy of
Sciences of the
United States...
